No 10Y consistency score yet for revenue — the window needs more comparable quarters.
Valuation vs own 10Y history: P/S 2.4x · 10Y median 3.8x · 15th percentile · as of Oct 6, 2026
Annualized revenue (TTM) · by quarter, last 27
Quarterly YoY revenue growth vs the 20% line
P/S multiple vs its 10Y median
FMP quote market capitalization / revenue from four consecutive issuer fiscal quarters. Quote observation: 2026-10-06T15:07:02.181Z. Latest historical point 2026-10-05. Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
Current FMP quote-based enterprise value / four-quarter operating income plus matched D&A. Quote observation: 2026-10-06T15:07:02.181Z. Latest historical point 2026-10-05. Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
FMP quote market capitalization / four-quarter operating cash flow. Quote observation: 2026-10-06T15:07:02.181Z. Latest historical point 2026-10-05. Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
FMP quote market capitalization / four-quarter operating cash flow less absolute capital expenditures. Quote observation: 2026-10-06T15:07:02.181Z. Latest historical point 2026-10-05. Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
Unrounded diluted TTM EPS / FMP quote price × 100. Quote observation: 2026-10-06T15:07:02.181Z. Latest historical point 2026-10-05.
Four-quarter operating EBITDA / current FMP quote-based enterprise value × 100. Quote observation: 2026-10-06T15:07:02.181Z. Latest historical point 2026-10-05. Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
Four-quarter operating cash flow / FMP quote market capitalization × 100. Quote observation: 2026-10-06T15:07:02.181Z. Latest historical point 2026-10-05. Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
Four-quarter free cash flow / FMP quote market capitalization × 100. Quote observation: 2026-10-06T15:07:02.181Z. Latest historical point 2026-10-05. Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
The latest delayed quote for Harmony Biosciences Holdings, Inc. (HRMY) stock was $39.83 as of Oct 6, 2026, 11:05 AM EDT, down 0.22% from the previous close.
Longer view (total return, dividends reinvested): past 12 months +46.1% · 3-year avg +7.4%/yr · 5-year avg +0.9%/yr
Harmony Biosciences Holdings, Inc. is a commercial-stage pharmaceutical firm dedicated to developing and marketing therapies for individuals in the United States who suffer from rare neurological conditions.
Biotechnology · Plymouth Meeting, PA
Selected amounts supplied by FMP for each displayed period. Reviewed label references appear where available; other labels are unverified, and items may overlap.
2023-12-31 · USD
Reviewed labels link to their filing; other labels are unverified FMP source labels.
Reviewed presentation labels and parent/child details link to filing evidence; other FMP source labels remain unverified. Mutual exclusivity and reconciliation to a total for the same reporting period and currency have not been verified; percentages and stacked totals are unavailable.
Next Earnings Date
Nov 3, 2026
28 days away
EPS Estimate
1.11
Revenue Est.
$274.55M
Last Quarter Results
EPS
$1.50
vs Estimate
$1.15
Revenue
| Stock | Market Cap | Close Price | Price Change | TTM Total Return | 5Y CAGR | 10Y CAGR | Compare |
|---|---|---|---|---|---|---|---|
| 1HRMY | $2.31B | $39.83 | -0.22% | +46.07% | +0.91% | N/A | N/A |
| 2RXRX | $2.34B | $4.46 | -6.69% | -12.88% | -25.86% | N/A | vs HRMY |
| 3NRIX | $2.35B | $22.64 | -1.05% | +142.89% | -5.51% | N/A | vs HRMY |
| 4MRVI | $2.25B | $8.16 | -4.24% | +174.40% | -27.63% | N/A | vs HRMY |
| 5ADMA | $2.37B | $10.23 | +1.24% | -30.91% | +54.74% | +3.85% | vs HRMY |
| 6LQDA | $2.38B | $26.76 | -3.18% | +23.11% | +59.01% | N/A | vs HRMY |
2.31
$261.28M
vs Estimate
$250.77M
Consensus Rating
Based on 11 analysts
Average Price Target
$47.64
+19.6% upside
Low
$30.00
Current
$39.83
High
$70.00
Quarterly
| Period | Low | Avg | High | # Analysts |
|---|---|---|---|---|
| Quarter ending Sep 2026 | $0.92 | $1.11 | $1.37 | 3 |
| Quarter ending Dec 2026 | $0.85 | $1.05 | $1.41 | 3 |
| Quarter ending Mar 2027 | $0.80 | $0.83 | $0.85 | 1 |
| Quarter ending Jun 2027 | $0.98 | $1.02 | $1.05 | 1 |
Annual
| Period | Low | Avg | High | # Analysts |
|---|---|---|---|---|
| FY 2026 | $3.54 | $3.94 | $4.63 | 6 |
| FY 2027 | $3.58 | $4.32 | $4.99 | 6 |
Quarterly
| Period | Low | Avg | High | # Analysts |
|---|---|---|---|---|
| Quarter ending Sep 2026 | $272.70M | $274.55M | $276.21M | 7 |
| Quarter ending Dec 2026 | $275.23M | $282.74M | $289.01M | 7 |
| Quarter ending Mar 2027 | $249.76M | $256.69M | $262.60M | 3 |
| Quarter ending Jun 2027 | $286.31M | $294.26M | $301.04M | 3 |
Annual
| Period |
|---|
Source: FMP Analyst Consensus Estimates. Forward P/E uses the consensus EPS estimate for the fiscal year ending Dec 31, 2026, matching Key Metrics.
| Low |
|---|
| Avg |
|---|
| High |
|---|
| # Analysts |
|---|
| FY 2026 | $1.02B | $1.03B | $1.12B | 9 |
| FY 2027 | $1.08B | $1.17B | $1.28B | 8 |
